Raya PM, et al. - Based on real-world evidence, researchers compared the long-term cost-effectiveness of IDegLira (fixed-ratio combination insulin degludec/liraglutide) with other regimens for type 2 diabetes in Spain. Clinical data were obtained from the European Xultophy Treatment Retrospective Audit (EXTRA) real-world evidence study where patients who did not meet glycemic targets were switched to IDegLira. It was found that IDegLira was cost-effective when compared to multiple daily-insulin injections (MDI) and basal insulin. According to long-term projections based on real-world evidence, IDegLira is likely to improve clinical results and decrease costs or be cost-effective vs other injectable regimens in type 2 diabetes patients in Spain.